134 related articles for article (PubMed ID: 15645679)
1. Cell culture-based assay of parvovirus B19 and the relevance of animal model viruses.
Blümel J
Dev Biol (Basel); 2004; 118():107-12. PubMed ID: 15645679
[TBL] [Abstract][Full Text] [Related]
2. Inactivation of parvovirus B19 and model viruses in factor VIII by dry heat treatment at 80 degrees C.
Roberts PL; El Hana C; Saldana J
Transfusion; 2006 Sep; 46(9):1648-50; author reply 1650. PubMed ID: 16965597
[No Abstract] [Full Text] [Related]
3. Evaluation of a new LightCycler reverse transcription-polymerase chain reaction infectivity assay for detection of human parvovirus B19 in dry-heat inactivation studies.
Prikhod'ko GG; Vasilyeva I; Reyes H; Wong S; Brown KE; Jameson T; Busby TF
Transfusion; 2005 Jun; 45(6):1011-9. PubMed ID: 15935001
[TBL] [Abstract][Full Text] [Related]
4. Inactivation of parvovirus B19 by liquid heating incorporated in the manufacturing process of human intravenous immunoglobulin preparations.
Yunoki M; Urayama T; Tsujikawa M; Sasaki Y; Abe S; Takechi K; Ikuta K
Br J Haematol; 2005 Feb; 128(3):401-4. PubMed ID: 15667545
[TBL] [Abstract][Full Text] [Related]
5. Removal of small non-enveloped viruses by nanofiltration.
Yokoyama T; Murai K; Murozuka T; Wakisaka A; Tanifuji M; Fujii N; Tomono T
Vox Sang; 2004 May; 86(4):225-9. PubMed ID: 15144526
[TBL] [Abstract][Full Text] [Related]
6. Quantitative NAT for pathogen inactivation verification.
McKenney K; Gillmeister L; Marlowe K; Armistead D; Burgess W; Drohan W
Dev Biol (Basel); 2004; 118():81-8. PubMed ID: 15645676
[TBL] [Abstract][Full Text] [Related]
7. Removal of small nonenveloped viruses by antibody-enhanced nanofiltration during the manufacture of plasma derivatives.
Kreil TR; Wieser A; Berting A; Spruth M; Medek C; Pölsler G; Gaida T; Hämmerle T; Teschner W; Schwarz HP; Barrett PN
Transfusion; 2006 Jul; 46(7):1143-51. PubMed ID: 16836561
[TBL] [Abstract][Full Text] [Related]
8. Viral safety of Nanogam, a new 15 nm-filtered liquid immunoglobulin product.
Terpstra FG; Parkkinen J; Tölö H; Koenderman AH; Ter Hart HG; von Bonsdorff L; Törmä E; van Engelenburg FA
Vox Sang; 2006 Jan; 90(1):21-32. PubMed ID: 16359352
[TBL] [Abstract][Full Text] [Related]
9. Inactivation of parvovirus B19 in human platelet concentrates by treatment with amotosalen and ultraviolet A illumination.
Sawyer L; Hanson D; Castro G; Luckett W; Dubensky TW; Stassinopoulos A
Transfusion; 2007 Jun; 47(6):1062-70. PubMed ID: 17524098
[TBL] [Abstract][Full Text] [Related]
10. Variability of parvovirus B19 to inactivation by liquid heating in plasma products.
Hattori S; Yunoki M; Tsujikawa M; Urayama T; Tachibana Y; Yamamoto I; Yamamoto S; Ikuta K
Vox Sang; 2007 Feb; 92(2):121-4. PubMed ID: 17298573
[TBL] [Abstract][Full Text] [Related]
11. Inactivation kinetics of model and relevant blood-borne viruses by treatment with sodium hydroxide and heat.
Borovec S; Broumis C; Adcock W; Fang R; Uren E
Biologicals; 1998 Sep; 26(3):237-44. PubMed ID: 10208725
[TBL] [Abstract][Full Text] [Related]
12. Different susceptibility of B19 virus and mice minute virus to low pH treatment.
Boschetti N; Niederhauser I; Kempf C; Stühler A; Löwer J; Blümel J
Transfusion; 2004 Jul; 44(7):1079-86. PubMed ID: 15225251
[TBL] [Abstract][Full Text] [Related]
13. Molecular mechanism underlying B19 virus inactivation and comparison to other parvoviruses.
Mani B; Gerber M; Lieby P; Boschetti N; Kempf C; Ros C
Transfusion; 2007 Oct; 47(10):1765-74. PubMed ID: 17880601
[TBL] [Abstract][Full Text] [Related]
14. Prevention of iatrogenic transmission of B19 infection: different approaches to detect, remove or inactivate virus contamination.
Bonvicini F; Gallinella G; Gentilomi GA; Ambretti S; Musiani M; Zerbini M
Clin Lab; 2006; 52(5-6):263-8. PubMed ID: 16812953
[TBL] [Abstract][Full Text] [Related]
15. Investigation of intrarenal viral infections in kidney transplant recipients unveils an association between parvovirus B19 and chronic allograft injury.
Barzon L; Murer L; Pacenti M; Biasolo MA; Della Vella M; Benetti E; Zanon GF; Palù G
J Infect Dis; 2009 Feb; 199(3):372-80. PubMed ID: 19099488
[TBL] [Abstract][Full Text] [Related]
16. Kinetics of inactivating human parvovirus B19 and porcine parvovirus by dry-heat treatment.
Blümel J; Stühler A; Dichtelmüller H
Transfusion; 2008 Apr; 48(4):790. PubMed ID: 18366462
[No Abstract] [Full Text] [Related]
17. Inactivation of parvovirus B19 during STIM-4 vapor heat treatment of three coagulation factor concentrates.
Berting A; Modrof J; Unger U; Gessner M; Klotz A; Poelsler G; Kreil TR
Transfusion; 2008 Jun; 48(6):1220-6. PubMed ID: 18410254
[TBL] [Abstract][Full Text] [Related]
18. Serologic and molecular detection of human Parvovirus B19 infection.
Peterlana D; Puccetti A; Corrocher R; Lunardi C
Clin Chim Acta; 2006 Oct; 372(1-2):14-23. PubMed ID: 16765338
[TBL] [Abstract][Full Text] [Related]
19. Use of bacteriophages as surrogates for mammalian viruses.
McAlister M; Aranha H; Larson R
Dev Biol (Basel); 2004; 118():89-98. PubMed ID: 15645677
[TBL] [Abstract][Full Text] [Related]
20. Effectiveness of nanofiltration in removing small non-enveloped viruses from three different plasma-derived products.
Menconi MC; Maggi F; Zakrzewska K; Salotti V; Giovacchini P; Farina C; Andreoli E; Corcioli F; Bendinelli M; Azzi A
Transfus Med; 2009 Aug; 19(4):213-7. PubMed ID: 19706139
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
